Abhay Gandhi
CEO North America
Notable Quotes
We still believe we have a competitive product. However, since the launch is delayed by, as you said, three quarters, I think the time to our expected peak will move a little.
We are pleased with the first cycle approval of Leqselvi by the U.S. FDA. This validates our team's capability to effectively bring treatments from research and development to approval.
We have consciously worked towards improving the realization for prescriptions. And that's working well.
We broadly see an acceptance that we have a strong product in our hands.
Generic REVLIMID sales were very small in this quarter.
I think it's better to look at the prescription trend, and sometimes the values will catch up.
I don't see a huge change in the environment as far as generics is concerned.
We haven't seen any negative impact because of the entry of the HUMIRA biosimilars.